



COVID-19 Update

JJC-April 2021



COVID-19 GLOBAL PORTRAIT

AstraZeneca Revises Coronavirus Vaccine Efficacy Rate Downward

Still, the company reports the vaccine remains highly effective at preventing symptomatic disease and 100% effective against stopping severe disease and

COVID updates: Brazil sets new record for daily deaths as Hong Kong suspends Pfizer vaccine — as it happened

By [Simon Smale](#) and [Michael Doyle](#)

Posted 2d ago, updated 1d ago

Surge in new cases of coronavirus across Japan


The Tokyo metropolitan government has reported the highest number of new coronavirus cases in a month, just three days after a state of emergency was lifted.

Tokyo officials confirmed 420 new infections Wednesday. It's the second tally this month to breach 400.

'Double mutant': What are the risks of India's new Covid-19 variant

By [Soutik Biswas](#)
India correspondent

🕒 25 March 2021 | [India](#)



Victoria will restart international flights on April 8 after an overhaul of its hotel quarantine system

By [Chanel Zagon](#) - 1 day ago



Victoria's revamped hotel quarantine program will fire up in a fortnight, with the government confident the system will pass the test this time.



Victoria will resume international flights on April 8 following an extensive overhaul of its hotel quarantine program.

World's Data


> 132 Million
Confirmed Cases

> 2,8 Million
Death Cases

> 550,000
Daily New Cases

Daily New Cases

Cases per Day
Data as of 0:00 GMT+0



Number of confirmed cases have increased about 4 million within the last 6 days

Worldometer, April 4th 2021

- New variant of Covid-19 called 'Double mutant' found in India
- Some countries already restart their international flights followed by strict quarantine procedure
- Some issues found after AstraZeneca Vaccination in some countries, causing decreased AstraZeneca's efficacy rate
- Strict adherence to health protocols is still the main key of prevention, even after vaccination

Global
Portrait

Indonesia
Dashboard

Death to
Discharge Rate

Siloam
Dashboard

Doubling
Rate

COVID
Testing and Vaccine

Siloam
Effort

Siloam
Advice

COVID-19 DASHBOARD: INDONESIA CURRENT SITUATION



1,537,967
Confirmed Cases

41,815

Death Cases
(2,7% of Confirmed)

114,475

Active Cases
(7,4% of Confirmed)

1,381,677

Recovered
(89,8% of Confirmed)

61,133

Suspects

Satgas: Jumlah Kematian COVID-19 Global Naik, Indonesia Turun

Tim detikcom - detikNews

Kamis, 25 Mar 2021 17:31 WIB

16 Juta Dosis Vaksin COVID-19 Sinovac Tiba Lagi di Indonesia


Versi terbaru per: 25/03/2021 Ghita Intan



Angka kesembuhan pasien Covid-19 Indonesia turun 6 minggu berturut-turut

Oleh: Yudho Winarto

Rabu, 24 Maret 2021 07:24 WIB



Wamenkes Sebut Vaksinasi Covid-19 Turunkan Jumlah Kasus Aktif di Indonesia

Kamis, 25 Maret 2021 13:52 WIB



+6,731 confirmed cases
+427 deaths

April 4 (recent peak)


April 5 (latest)

+3,712 confirmed cases
+146 deaths

- The most recent peak happened on 4th April when for the first time since early March Indonesia hits >6500 confirmed case in one day

- COVID-19 Large Scale Social Restriction (PSBB) are extended until 19th April 2021
- KADIN started to open the registration for Gotong Royong Vaccination Program
- Beside vaccination for elderly, Indonesia started vaccination for teachers and other frontliners of public services
- Government considering to start normal school (offline) after all teachers being vaccinated

SOURCE: COVID19.GO.ID (Updated 5 April 2021)



Indonesia's latest weekly death to recovery rate remained stable at ~2.2%

(CUMULATIVE) COUNTRIES - DEATH vs RECOVERED || SHG – DEATH vs DISCHARGED RATE


World Data as of 5 Apr, 16:19 GMT | Siloam Data as of 31 Mar, 10:40 WIB



Siloam Hospitals is well equipped to treat Covid-19 patients around Indonesia

SILOAM HOSPITALS COVID-19 TOTAL OPERATIONAL BED ALLOCATION

As of 6 April 2021



COVID-19 DASHBOARD: SILOAM DASHBOARD

As of 6 April 2021

Total COVID Patients

19, 775


Current Hospitalized
COVID Patients

359



S. Korea, Thailand, and Italy's doubling rate improved in the last 2 weeks; China, India, and US' doubling rate worsened


S. KOREA'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021




INDIA'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021




THAILAND'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021




UNITED STATE'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021



CHINA'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021



ITALY'S DOUBLING RATE
27 Mar 2020 – 31 Mar 2021




SOURCE: WORLDOMETER

- In India, the rise in cases were predicted to be contributed from poor adherence to safety protocols, due to a false optimism from the decreasing cases

Indonesia's latest doubling rate continued to improve and reached its highest record at 284 days

INDONESIA DOUBLING RATE


27 Mar 2020 – 31 Mar 2021



DKI Jakarta's Doubling rate

27 Mar 2020 – 31 Mar 2021


Total case: 361,535



Jawa Timur's Doubling rate

27 Mar 2020 – 31 Mar 2021


Total case: 134,852



Sumatera Selatan's Doubling rate

27 Mar 2020 – 31 Mar 2021


Total case: 16,643



Sulawesi Selatan's Doubling rate

27 Mar 2020 – 31 Mar 2021

Total case: 58,369




SOURCE: KEMENTERIAN KESEHATAN, KOMPAS.COM, DETIK.COM

In worse scenario, Indonesia's active cases may increase by 27%. In the best possible scenario, active cases may decrease by -36%


INDONESIA DOUBLING RATE

27 Mar 2020 – 30 Jun 2021




DAILY CASES, CUMULATIVE CASES, AND ACTIVE CASES

27 Mar 2020 – 30 Jun 2021



Indonesia's latest volume of people tested surpassed WHO standard of 38.1k per day; however positivity rate has yet to reach <5%

INDONESIA COVID-19 TESTING
2 Mar 2020 – 31 Mar 2021



As of 31 March 2021, only 3.1% (8.5mn people) of Indonesia population were tested for Covid


SOURCE: KAWAL COVID

Covid-19 Testings





SILOAM HOSPITAL'S CONTINUOUS EFFORT: TESTING CAPACITY

SGH - Weekly Average Number of Swab, Rapid, and Serology Tests (As of April 5th)



COVID TESTING COMPARISON - THESE ARE NOT 'ONE SIZE FITS ALL' TYPE OF TESTING, THE EFFECTIVENESS OF THE TESTING BASED ON INFECTION PERIOD



New Technology - Quantitative Serology



Key Objectives:
Quantitative Serology Test is immunoassay for the **in vitro quantitative determination of antibodies (including IgG) to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike (S) protein receptor binding domain (RBD) in human serum and plasma.**




What it is for
The test is intended to **assess the immune response to the SARS-CoV-2.**



Sample Collection
Blood serum and plasma



Key Takeaway
This test can only measure the quantity of antibodies to the spike protein of the coronavirus, which could signal whether a person has been already infected and potentially developed immunity to the virus.



Features



High performance

- Sensitivity 98.8%
- Specificity 99.98%



Quantify the titer of antibodies




- **FDA** approved for Emergency Use Authorization
- **USA** based technology with CE Europe certificate

Benefit

- Definitive answer about the body's immune response to the virus.
- Identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19
- Useful to complement NAAT (Molecular test) for diagnosis
- Determination of seroprevalence in a given population
- Determination of antibody positivity to determine (presumed) immunity
- Characterize vaccine-induced immune response
- Determine antibody levels in plasmapheresis donations for preparation of therapeutic Ig formulations

Reference:
Centers of Disease Control and Prevention, 2020 ; Roche Elecsys Anti-SARS-CoV-2 S fact sheet ; Roche Elecsys Anti-SARS-CoV-2 S IFU, Benefits, Information, and claims has not been internally validated by Siloam Hospitals and is taken or quoted from manufacturer sources.






Covid-19 **Vaccination**

GLOBAL DEVELOPMENT: CORONAVIRUS VACCINE TRACKER

By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021



• Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals.

Leading vaccines

| Developer | How It Works | Phase | Status |
|--------------------|--------------|-------|--|
| Pfizer-BioNTech | mRNA | 2 3 | Approved in several countries. Emergency use in U.S., E.U., other countries. |
| Moderna | mRNA | 3 | Approved in Switzerland. Emergency use in U.S., U.K., E.U., others. |
| Gamaleya | Ad26, Ad5 | 3 | Early use in Russia. Emergency use in other countries. |
| Oxford-AstraZeneca | ChAdOx1 | 2 3 | Approved in Brazil. Emergency use in U.K., E.U., other countries. |
| CanSino | Ad5 | 3 | Approved in China. Emergency use in Mexico, Pakistan. |
| Johnson & Johnson | Ad26 | 3 | Emergency use in U.S., E.U., Bahrain. |
| Vector Institute | Protein | 3 | Early use in Russia. |
| Novavax | Protein | 3 | |
| Sinopharm | Inactivated | 3 | Approved in China, U.A.E., Bahrain. Emergency use in other countries. |
| Sinovac | Inactivated | 3 | Approved in China. Emergency use in other countries. |
| Sinopharm-Wuhan | Inactivated | 3 | Approved in China. Limited use in U.A.E. |
| Bharat Biotech | Inactivated | 3 | Emergency use in India, Iran, Zimbabwe. |

Vaccine Safety

- The FDA has been very clear about the conditions under which it would issue an emergency use authorization (EUA) or full approval for any COVID-19 vaccine candidate intended for public use.
- Vaccine developers report side effects that include pain at the injection site, fever, muscle aches, fatigue and headaches, mostly lasting about a day or two.


Vaccination Procedure

- Most COVID-19 Vaccine by 2 doses of intramuscular (IM) injection given separately after 14 – 28 days, except for Johnson & Johnson which only need 1 dose

GLOBAL COVID-19 VACCINATION

SOURCE: BLOOMBERG
UPDATED: 5TH APRIL 2021

World Map of Vaccination



| Country | Doses administered ▼ | Enough for % of people | % of population | | Daily rate of doses administered |
|--------------|----------------------|------------------------|-----------------|------------------|----------------------------------|
| | | | given 1+ dose | fully vaccinated | |
| Global Total | 658,955,807 | - | - | - | 16,541,292 |

The biggest vaccination campaign in history is underway. More than **658 million doses** have been administered across 151 countries, according to data collected by Bloomberg. The latest rate was roughly **16.5 million doses a day**.



Top 15 Countries with Highest Vaccination


| Country | Doses administered ▼ | Enough for % of people | % of population | | Daily rate of doses administered |
|--------------|----------------------|------------------------|-----------------|------------------|----------------------------------|
| | | | given 1+ dose | fully vaccinated | |
| Global Total | 658,955,807 | - | - | - | 16,541,292 |
| U.S. | 165,053,746 | 25.5 | 32.0 | 18.5 | 3,084,436 |
| China | 136,677,000 | 4.9 | - | - | 4,894,286 |
| EU | 79,435,098 | 8.9 | 12.3 | 5.2 | 1,667,454 |
| India | 75,979,651 | 2.8 | 4.8 | 0.7 | 2,244,267 |
| U.K. + | 36,904,755 | 27.6 | 47.2 | 8.1 | 460,855 |
| Brazil | 23,679,963 | 5.6 | 8.8 | 2.5 | 922,312 |
| Turkey | 16,796,949 | 10.1 | 11.6 | 8.6 | 297,377 |
| Germany | 14,381,068 | 8.7 | 12.1 | 5.2 | 293,808 |
| Indonesia | 12,649,124 | 2.4 | 3.2 | 1.5 | 307,325 |
| France | 12,422,460 | 9.6 | 14.3 | 4.8 | 289,745 |
| Italy | 11,038,465 | 9.1 | 12.6 | 5.7 | 246,199 |
| Chile | 10,786,331 | 28.2 | 36.3 | 20.1 | 162,799 |
| Russia | 10,600,000 | 3.6 | 4.3 | 2.9 | 300,000 |
| Israel | 10,075,724 | 55.7 | 58.1 | 53.2 | 20,643 |

In **Indonesia**, the latest vaccination rate is **307,325 doses** per day, on average. At this pace, it will take another **3.5 years** to cover **75%** of the population.

Countries' Cases Growth v.s. Vaccination Progress


INDIA

1 Sep - 31 Mar 2021




SINGAPORE

1 Sep - 31 Mar 2021



USA

1 Sep - 31 Mar 2021




ISRAEL

1 Sep - 31 Mar 2021



UK

1 Sep - 31 Mar 2021



JAPAN

1 Sep - 31 Mar 2021




- All India Institute of Medical Sciences and John Hopkins University predicted that India and USA will soon reach herd immunity

SOURCE: OURWORLDINDATA, KAWAL COVID, TELEGRAPH

Indonesia's vaccination progress is slightly behind when compared among selected countries

COUNTRIES' VACCINATION PROGRESS

As of 31 Mar 2021



(People vaccinated/country population)

| | Vaccination Start Date | Latest 7-day avg. people vaccinated | People vaccinated (1st dose) | Population |
|-----------|------------------------|-------------------------------------|------------------------------|---------------|
| ISRAEL | 19-Dec-20 | 5,731 | 5,244,872 | 8,655,541 |
| UK | 13-Dec-20 | 308,037 | 31,147,444 | 67,886,004 |
| CHILE | 24-Dec-20 | 106,654 | 6,804,660 | 19,116,209 |
| USA | 20-Dec-20 | 1,731,589 | 97,593,290 | 331,002,647 |
| SINGAPORE | 11-Jan-21 | 144,307 | 943,307 | 5,850,343 |
| BRAZIL | 17-Jan-21 | 396,087 | 14,921,376 | 212,559,409 |
| INDIA | 16-Jan-21 | 1,562,380 | 55,783,201 | 1,380,004,385 |
| INDONESIA | 13-Jan-21 | 246,554 | 8,115,714 | 273,523,621 |
| JAPAN | 17-Feb-21 | 400,508 | 877,159 | 126,476,458 |

SOURCE: OUR WORLD IN DATA, NYTIMES


- More than 448 million vaccine doses have been administered worldwide.

Indonesia aims to vaccinate 181.5 million people within a year as an effort to reach herd immunity

INDONESIA VACCINATION

13 Jan 2021 – 31 Mar 2021

Latest 7-day daily average for 1st dose was at 246,554 vaccinations




SOURCE: KAWAL COVID, OURWORLDINDATA

- Inoculation of 2nd dose in Phase 2 is slower because elderly population gets their 2nd dose after 28 days (compared to 14 days for younger population).
- Indonesia expects to receive 20.2 million doses of COVID-19 vaccines developed by Moderna Inc MRNA.O and China's Sinopharm from the second quarter to use in a private vaccination scheme.

Indonesia's growth of cases has shown great improvement despite only having 3% population vaccinated


INDO CASES GROWTH V.S. VACCINATION PROGRESS

1 Sep - 31 Mar 2021



INDO WEEKLY TESTING V.S. VACCINATION PROGRESS

1 Sep - 31 Mar 2021










- Indonesia's weekly testing volumes are likely to be lower as more people get vaccinated

Comparing COVID-19 Vaccines

Comparing vaccines

| DEVELOPER | TYPE | DOSES |
|---|----------------------|-----------------------------|
| Pfizer-BioNTech US, Germany | mRNA | ●● 2 doses 3 weeks apart |
| Moderna US | mRNA | ●● 2 doses 4 weeks apart |
| Oxford-AstraZeneca UK, Sweden | Viral vector | ●● 2 doses 4-12 weeks |
| Sinopharm China | Inactivated virus | ●● 2 doses 3-4 weeks |
| Sinovac China | Inactivated virus | ●● 2 doses 3 weeks apart |
| Gamaleya Russia | Viral vector | ●● 2 doses 2 weeks apart |
| Johnson & Johnson US | Viral vector | ● 1 dose |

Comparing vaccines

| DEVELOPER | COST PER DOSE ** (US\$) |
|---|---|
| Pfizer-BioNTech US, Germany |  \$19.5 |
| Moderna US |  \$25 to \$37 |
| Oxford-AstraZeneca UK, Sweden |  \$3 to \$4 |
| Sinopharm China |  \$31 |
| Sinovac China |  \$31 |
| Gamaleya Russia |  <\$10 |
| Johnson & Johnson US |  \$10 to \$14.50 |

** Exact prices of procurement for different countries vary.

- Johnson & Johnson is the only vaccine need one dose of injection, while others require 2 doses
- Moderna has the most expensive cost per dose followed by Sinopharm and Sinovac

SOURCE: WHO, health authorities, relevant firms

SCMP

Global
Portrait

Indonesia
Dashboard

Death to
Discharge Rate

Siloam
Dashboard


Doubling
Rate

COVID
Testing and Vaccine

Siloam
Effort

Siloam
Advice


Government Plan: Vaccination Phases



Minister of Health press conference, 08-Feb-2021

Notes:

1. Vaccination is first prioritized for healthcare personnel, then for other individuals aged 18-59 years.
2. Healthcare worker over 60 years old will received vaccination per 08-February 2021. 2nd Dose will be given 1month prior 1st dose
3. Individuals over 60 years old will receive vaccination after the vaccine safety data is available (as written in the EUA or in the phase III clinical trial report).
4. Vaccines can be given to recipients with well-controlled comorbidities: pending criteria from ITAGI (Indonesian Technical Advisory Group on Immunization) or other experts).




Government Plan: Vaccine Procurement Plan

| No | Brand | Number of doses | | ETA |
|-------------------------------|-------------|---|--------------------|---------------------|
| | | Firm order | Potential order | |
| 1 | Sinovac | 3,000,000 | - | Dec 2020 |
| | | 122,504,000 | - | Dec 2020 - Jan 2022 |
| | | | 100,000,000 | Sep 2021 - Mar 2022 |
| 2 | Novavax | 50,000,000 | 80,000,000 | Jun 2021 - Mar 2022 |
| 3 | AstraZeneca | 50,000,000 (agreement being finalized, volume confirmed) | 50,000,000 | Q2 2021 - Q1 2022 |
| 4 | Pfizer | 50,000,000 (agreement being finalized, volume confirmed) | 50,000,000 | Q3 2021 - Q1 2022 |
| 5 | Gavi COVAX | 54,000,000 | 54,000,000 | Q2 2021 - Q1 2022 |
| Total | | 329,504,000 | 334,000,000 | |
| Firm + potential order | | | 663,504,000 | |
| Total vaccine needs | | | 426,800,000 | |

Minister of Health press conference, 29-Dec-20

Other Vaccine Candidates

- Sinopharm
- Moderna



Gotong Royong Vaccination

Definition



Vaksin Gotong Royong is vaccination program for employees, family members, and other individuals in the family, which **funding is borne** by the corporations/agencies/entities where the employee work.

Every individuals who has been vaccinated for COVID-19 will be given Vaccination **Certificate**. For travelling purposes, individuals enrolled in *Vaksin Gotong Royong* program will be given COVID-19 vaccination card or Vaccination e-Certificate as regulated in International Certificate of Vaccination (ICV)

Global Case Studies



Mega Immunization Program in India


The health ministry announce its decision to involve private hospital on the country’s immunization drive for COVID-19. The amount to be paid is still yet to be discussed. One of the vaccine use is Covishield, vaccine developed by researchers at the Oxford university and the British-Swedish firm AstraZeneca that are being manufactured by Serum Institute of India (SII). The second vaccine is Hyderabad-based Bharat Biotech’s Covaxin.

Insurance Company to support vaccination in Singapore

Bank and insurance company support their employee and customer to get vaccinated by giving reassurances. Hospital benefits, free medical consultation, day off, work from home benefits etc will be given if they have experienced any side effect from vaccination.

Initiatives in Israel

- Government sending medical workers to major corporations to do vaccination on site
- Private firms incentivizing staff to get vaccinated through cash and salary bonus incentive
- Private firms some are imposing bans on non-vaccianted staffs to work



Gotong Royong Vaccination Indonesia

Updates per 25th February 2021

Gotong Royong Vaccine

- The vaccine used for private vaccination must differ from free, public vaccination
- *Vaksin Gotong Royong* must use the vaccine imported by PT Bio Farma (Persero), in accordance with the needs of corporates

The People


- *Vaksin Gotong Royong* can only be bought by corporates through PT Bio Farma (Persero), to be used to their employees and their family members for free
- *Vaksin Gotong Royong* does not abolish citizens' right for free, public vaccination
- Staffs of Foreign Offices and International Non-Profit Organizations working in Indonesia are allowed to join public vaccination and *Vaksin Gotong Royong*
- How corporates can buy from PT Bio Farma (Persero) for *Vaksin Gotong Royong* program for their staffs, still being formularized. Will be announced at a later date

Distribution and Healthcare Facilities


- Distribution of Covid-19 Vaccine for *Vaksin Gotong Royong* is done by PT Bio Farma to Public / Private Healthcare Facilities that has partnered with corporates.
- *Vaksin Gotong Royong* can only be done in Public / Private Healthcare Facilities that has fulfilled government regulatory requirements
- Healthcare Facilities administering *Vaksin Gotong Royong* should be different from those administering public vaccination
- Vaccination of *Vaksin Gotong Royong* is done on partnership between corporates working with Healthcare Facility

Tariff and Other Info

- Maximum tariff for *Vaksin Gotong Royong* vaccination will be set by Minister. Maximum tariff will be announced at a later date
- Government (KADIN) have already close its 2nd phase of registration on 24th March 2021.
- Government is still evaluating 'open vaccination program', it is an option, but no regulation has been released yet




Private Vaccination: How it works



Siloam Hospital's Continuous Effort: Vaccination

(As of March 29th)



- Siloam has received several dose of COVID-19 Vaccines and has been listed as healthcare facility to do vaccination.
- We have successfully giving more than 77.000 dose of vaccines for our frontliners as well as for public (elderly, teachers, lecturers, civil workers etc) until 29th March 2021

SILOAM HOSPITALS PRIORITIZES PATIENT EXPERIENCE

Quality Care



Clinical Protocol Update & International Benchmarking



Dedicated Doctors & Other Medical Practitioners



Ensuring enough capacity and equipment for all patients



Ensuring safety with strict health protocol



High Quality PPE



Clean & Safe Hospitals

Service Innovation



Drivethru Booth



Home Care



Online Consultation



Educative Webinars



Seamless Booking



Coping Program



COVID-19 Consulting

New Corporate Service



COVID-19 Antibody Index

Specially designed tool to analyze profile and demographic of COVID-19 vaccination in the company, including development of antibody after the vaccination

COVID-19 Testing & Screening



Availability of Various Testing Methods
(Rapid Test, Serology Test, PCR Swab Test, Isothermal Test)



Contact Tracing Protocol



Ensuring Test Capacity Across all Hospital Units



Pre and Post Vaccination MCU Packages

New Screening Technique



Quantitative Serology

Immunoassay for the in vitro quantitative determination of antibodies (including IgG) to the SARS-CoV-2

Global
Portrait

Indonesia
Dashboard

Death to
Discharge Rate

Siloam
Dashboard

Doubling
Rate

COVID
Testing and Vaccine

Siloam
Effort

Siloam
Summary



THANK YOU

Pre-questions : 事前質問

【質問タイプ 1 : ワクチン接種プログラムについて】

- ① 外国人（駐在員）も、自主接種プログラム（Gotong Royong）でワクチンを接種する事は可能か？
→自主接種プログラムは、外国人も接種対象になっております。
- ② 自主接種プログラムでは、どの種類のワクチンを接種する事になるか？
→現時点ではSINOPHARM社製と、MODERNA社製の2種類が予定されております。
- ③ 接種するワクチンの種類を選ぶことが出来るか？
→ワクチンの種類を選択する事は出来ません。自主接種プログラムではSINOPHARM社製によるワクチン接種が先行開始される予定で、MODERNA社製のワクチン接種は年後半から開始される予定です。
- ④ 自主接種プログラムに参加する為には、何をすれば良いか？
→各企業にて、インドネシア商工会議所（KADIN）と提携医療機関に夫々登録を頂く必要が御座います。KADINにご登録頂いた情報は国営製薬企業である BIO FARMA社に共有され、後日登録内容に基づいてBIO FARMA社より各企業に請求のご案内が届く予定です。
- ⑤ 自主接種プログラムで使用するワクチンは、どの様に確保・供給されるのか？
→BIO FARMA社が一括管理致します。
- ⑥ 自主接種プログラムは何時開始するか？
→開始時期については、未だ政府・KADINより正式な発表は御座いません。
- ⑦ 自主接種プログラムにおけるワクチン接種の値段は幾らか？
→ワクチンの価格についても、未だ正式発表がない状況です。
- ⑧ インドネシアにて、ワクチン接種後に重大な副反応が起きた症例は存在するか？
→発熱等の軽微なケースの他、アナフィラキシーも確認されておりますが、同副反応はその他ワクチンでも起こり得るものであり、新型コロナウイルスワクチンに限定される副反応は現時点で確認しておりません。尚、シロアム病院では万が一の場合に備え、ワクチン接種時にはMini ICUと救急車の準備をしております。
- ⑨ 副反応に対する政府補償の詳細を教えてください。
→インドネシア政府として、外国人を含む全ての接種者に対し、重度の副反応が発生した場合の補償を表明しております。
- ⑩ 外国人（駐在員）は、政府によるワクチン接種プログラムには現時点で参加できない理解で正しいか？
→原則、外国人は政府プログラムでのワクチン接種は非対象になっております。

Pre-questions

【質問タイプ2：一般医療事情について】

① コロナ患者対応病院における、現在の病床稼働率ほどの程度か？

→シロアム病院では約70%となっております。年始は一般病床/ICUとも満床に近い状況でしたが、その後徐々にですが稼働率は下がってきております。

② シロアム病院には、人工呼吸器・ECMOが十分に備わっているか？

→人工呼吸器は十分に御座いますが、ECMOは導入しておりません。

【質問タイプ3：シロアム病院について】

① ワクチン自主接種プログラムにてシロアム病院を登録したい場合、どのようなプロセスが必要か？

→シロアム病院のウェブサイト (<https://e-form.siloamhospitals.com/vaksingotongroyong/>) から登録が可能です。

具体的な登録プロセスにつきましては、別途添付させて頂くレターもご参照ください。

② ジャカルタ以外の都市にあるシロアム病院でも、ワクチン接種は可能か？

→シロアムグループの各病院（39病院、21都市）どちらでも接種可能です。病院所在地につきましては添付URLをご参照ください。

(<https://www.siloamhospitals.com/Hospitals-and-Clinics/Hospitals/Find-nearest-Hospitals>)

③ 日本人もコロナ感染によりシロアム病院にて入院をされているか？

→シロアム病院でも、新型コロナウイルス関連で日本人の患者様にご入院頂いております。

その他に何かご不明な点等が御座いましたら、ご遠慮なく下記連絡先までお問合せ下さい。

笠井 洋 (Hiroshi Kasai)

PT Siloam International Hospitals Tbk

Mobile (WA): +62-8118562762

E-mail: hiroshi.kasai@siloamhospitals.com